Thoracic Cancer | |
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China | |
Cuiying Zhang1  Qingwei Meng2  Guangyuan Lou3  Hui Guo4  Hong Sun4  Yu Yao4  Bei Xu5  Yangchun Gu6  Bin Ai7  Junling Li8  Yan Wang8  Anwen Liu9  Hongmin Lu1,10  Yongjie Shui1,11  Xia Song1,12  Cuimin Ding1,13  Meijun Song1,14  Peifeng Chen1,15  Tingyu Tang1,16  Zhiqiang Han1,17  Qing Zhou1,18  Dongming Zhang1,18  Mengzhao Wang1,18  Xiangning Liu1,18  Wei Zhong1,18  Xiaoxing Gao1,18  Yuequan Shi1,18  Jing Zhao1,18  Minjiang Chen1,18  Jia Liu1,18  Xiaoyan Liu1,18  Yan Xu1,18  Jian Fang1,19  Chengzhi Zhou2,20  | |
[1] Cancer Center People's Hospital Huhehot China;Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin China;Department of Medical Oncology The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou China;Department of Medical Oncology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China;Department of Medical Oncology Zhongshan Hospital Fudan University Shanghai China;Department of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing China;Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing China;Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China;Department of Oncology The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang China;Department of Oncology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai China;Department of Radiation Oncology, The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China;Department of Respiratory Medicine Shanxi Provincial Cancer Hospital Taiyuan China;Department of Respiratory Medicine The Fourth Hospital of Hebei Medical University Shijiazhuang China;Department of Respiratory Medicine Zhejiang Provincial People's Hospital Zhejiang China;Department of Respiratory Medicine and Critical Care Medicine Zhuji People's Hospital Zhejiang China;Department of Respiratory Medicine, Affiliated Zhejiang Hospital Zhejiang University School of Medicine Zhejiang China;Department of Respiratory and Critical Care Medicine Quzhou People's Hospital Zhejiang China;Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China;Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Peking University Cancer Hospital and Institute Beijing China;State Key Laboratory of Respiratory Disease National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University Guangzhou China; | |
关键词: advanced lung cancer; immune checkpoint inhibitors; immune‐related adverse events; real‐world data; | |
DOI : 10.1111/1759-7714.14274 | |
来源: DOAJ |
【 摘 要 】
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. Methods A multicenter observational study was conducted. Medical records of lung cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types of ICIs included antiprogrammed cell death 1 or antiprogrammed cell death ligand 1 (PD‐L1) monotherapy, anticytotoxic T‐lymphocyte antigen‐4 monotherapy, or combination therapy. Results In total, 1905 patients with advanced lung cancer were evaluated. The median age was 63 (range 28–87) years, and the male/female ratio was 3.1:1 (1442/463). The primary histological subtype was adenocarcinoma (915). A total of 26.9% (512/1905) of the patients developed 671 irAEs, and 5.8% (110/1905) developed 120 grade 3–5 irAEs. Median duration from ICI initiation to irAEs onset was 56 (range 0–1160) days. The most common irAEs were thyroid dysfunction (7.2%, 138/1905), pneumonitis (6.5%, 124/1905), and dermatological toxicities (6.0%, 115/1905). A total of 162 irAEs were treated with steroids and 11 irAEs led to death. Patients with positive PD‐L1 expression (≥1%) and who received first‐line ICI treatment developed more irAEs. Patients who developed irAEs had a better disease control rate (DCR, 71.3% [365/512] vs. 56.0% [780/1145]; p < 0.001). Conclusions The incidence rate of irAEs was 26.9% in a real‐world setting. IrAEs might be related to a better DCR, but clinicians should be more aware of irAE recognition and management in clinical practice.
【 授权许可】
Unknown